Month: September 2026

Military controls production will move to the company’s new, state-of-the-art Spartanburg site; smaller, select product lines are under agreement to be sold, along with the Santa Clarita campus

FORT COLLINS, Colo., Sept. 21, 2026 (GLOBE NEWSWIRE) — Woodward, Inc. (NASDAQ: WWD), a world leader in aerospace and industrial control solutions, today announced its plans to transition production out of its Santa Clarita, California, facility to streamline its portfolio and refine its manufacturing footprint.

Production of military fixed-wing and rotorcraft flight control actuation will move to Woodward’s world-class aerospace manufacturing campus in Spartanburg, South Carolina, which is currently in advanced stages of construction. Separately, Woodward has agreed to sell a smaller group of legacy commercial rotorcraft, land systems, and business jet products made in Santa Clarita, along with the campus itself, in a transaction expected to close in fiscal year 2027. 

“We don’t make decisions like this without recognizing what they mean for the people affected. Our team in Santa Clarita has contributed to Woodward for 17 years, and we are committed to supporting them through the transition with respect,” said Shawn McLevige, President of Woodward’s Aerospace segment. “This decision is in line with our strategy to continue creating value for our company and our shareholders through growth, operational excellence, and innovation. Moving this production to Spartanburg will help refine our manufacturing footprint to best support our customers and improve our supply chain as we meet increasing demand for industry-leading controls on current and next-generation commercial and military aircraft.” 

Woodward is expected to cease operations at the Santa Clarita facility no later than December 2027. The decision is expected to affect about 400 roles at the facility, with phased transitions through the planned move. The Spartanburg facility is expected to go online in the summer of 2027 and as previously announced, will produce Airbus A350 spoiler actuation systems, in addition to the transferred product lines and other aerospace components.

About Woodward

Woodward is the global leader in the design, manufacture, and service of energy conversion and control solutions for the aerospace and industrial equipment markets. Our purpose is to design and deliver energy control solutions our partners count on to power a clean future. Our innovative fluid, combustion, electrical, propulsion, and motion control systems perform in some of the world’s harshest environments. Woodward is a global company headquartered in Fort Collins, Colorado, USA. Visit our website at www.woodward.com.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Woodward’s plans to cease operations at its Santa Clarita facility; transfer production of certain product lines to its Spartanburg, South Carolina facility; divest the Santa Clarita campus and certain product lines primarily produced there; complete, open, and ramp up the Spartanburg facility; as well as the anticipated timing and sequencing of these actions and the anticipated operational, financial, and strategic benefits thereof. These statements are based on current expectations and assumptions and are not guarantees of future performance. Actual results may differ materially due to risks and uncertainties, including: (1) delays, disruptions, reduced capacity or productivity, quality-control issues, difficulties transferring equipment, processes, and institutional knowledge, delays in obtaining customer or regulatory approvals, supply-chain and logistics challenges, and higher-than-anticipated costs associated with the production transfer; (2) construction, permitting, equipment installation, qualification, labor, material, or other challenges that delay or prevent the Spartanburg facility from becoming operational or achieving expected production levels; (3) the possibility that the divestiture may not be completed on the anticipated terms or timeline or at all, including because of unsatisfied closing conditions or required approvals or consents, as well as business disruptions, adverse effects on business relationships, and difficulties with separation, transition services, supply arrangements, or operational handoffs; (4) the possibility that these actions may not occur in the anticipated sequence or on compatible timelines or, individually or collectively, may not achieve the anticipated benefits, or that such benefits may be delayed, less significant, or more costly to achieve than expected; and (5) other risk factors, risks, and uncertainties described in Woodward’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and any subsequently filed Quarterly Report on Form 10-Q and other SEC filings. Forward-looking statements speak only as of the date of this press release, and Woodward undertakes no obligation to update them except as required by law.

MEDIA CONTACTS

Jennifer Regina 
Vice President, Communications
+1 970-559-8840 
Jennifer.regina@woodward.com 

Dan Provaznik
Director, Investor Relations
+1 970-498-3849
Dan.Provaznik@Woodward.com

BROOKFIELD, NEWS, Sept. 21, 2026 (GLOBE NEWSWIRE) — Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced the pricing of a public offering of $600 million principal amount of senior notes due 2031 (the “notes”), which will bear interest at a rate of 5.650% per annum. The offering is expected to close on September 23, 2026, subject to the satisfaction of customary closing conditions.

The notes will be issued by Brookfield Finance Inc., an indirect wholly-owned subsidiary of Brookfield (the “issuer”), and will be fully and unconditionally guaranteed by Brookfield. It is expected that the net proceeds from the sale of the notes will be used for general corporate purposes.

The notes are being offered under Brookfield and the issuer’s existing base shelf prospectus filed in the United States and Canada and pursuant to an effective combined registration statement on Form F-10 on file with the U.S. Securities and Exchange Commission (the “SEC”) (File Nos. 333-292304-04 and 333-292304). Copies of the prospectus supplement and accompanying base shelf prospectus may be obtained free of charge on EDGAR at www.sec.gov/edgar or on SEDAR+ at www.sedarplus.ca. Before you invest, you should read these documents and other public filings by Brookfield for more complete information about Brookfield and this offering.

Alternatively, copies can be obtained from the joint book-running managers and underwriters:

Deutsche Bank Securities Inc. 1 Columbus Circle New York, NY 10019 Attn.: Prospectus Group Telephone: 1-800-503-4611 Email: prospectus.CPDG@db.com	BofA Securities, Inc. NC1-022-02-25 201 North Tryon Street Charlotte, NC 28255-0001 Attn: Prospectus Department Telephone: 1-800-294-1322 Email: dg.prospectus_requests@bofa.com

This news release does not constitute an offer to sell or the solicitation of an offer to buy the notes described in this news release, nor will there be any sale of these notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The notes being offered have not been recommended, approved or disapproved by the SEC or any regulatory authority, nor has any such authority passed upon the accuracy or adequacy of the base shelf prospectus or the prospectus supplement.

About Brookfield Corporation

Brookfield Corporation is a leading global investment firm focused on building long-term wealth for institutions and individuals around the world. We have three core businesses: Asset Management, Wealth Solutions, and our Operating Businesses which are in infrastructure, energy, private equity and real estate.

We have a track record of delivering 15%+ annualized returns to shareholders for over 30 years, supported by our investment and operational experience. Our conservatively managed balance sheet, extensive operational experience and global sourcing networks allow us to consistently access unique opportunities. At the center of our success is the Brookfield Ecosystem, which is based on the fundamental principle that each group within Brookfield benefits from being part of the broader organization. Brookfield Corporation is publicly traded in New York and Toronto (NYSE: BN, TSX: BN).

For more information, please contact:

Media:	Investor Relations:
Kerrie McHugh	Katie Battaglia
Tel: (212) 618-3469	Tel: (416) 359-8544
Email: kerrie.mchugh@brookfield.com	Email: katie.battaglia@brookfield.com

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of Canadian provincial securities laws and “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and in any applicable Canadian securities regulations (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, beliefs and assumptions and which in turn are based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. The estimates, beliefs and assumptions of Brookfield are inherently subject to significant business, economic, competitive and other uncertainties and contingencies regarding future events and as such, are subject to change. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may” and “should” and similar expressions. In particular, the forward-looking statements contained in this news release include statements referring to the offering, the expected use of proceeds from the offering and the expected closing date of the offering.

Although Brookfield believes that such forward-looking statements are based upon reasonable estimates, beliefs and assumptions, certain factors, risks and uncertainties, which are described from time to time in our documents filed with the securities regulators in Canada and the United States, not presently known to Brookfield, or that Brookfield currently believes are not material, could cause actual results to differ materially from those contemplated or implied by forward-looking statements.

Readers are urged to consider these risks, as well as other uncertainties, factors and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements, which are based only on information available to us as of the date of this news release. Except as required by law, Brookfield undertakes no obligation to publicly update or revise any forward-looking statements, whether written or oral, that may be as a result of new information, future events or otherwise.

CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT

NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) — Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit taking place virtually September 23, 2026.

The fireside chat will be webcast live on Wednesday, September 23, 2026 at 9:00 a.m. EDT.

To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma’s investor relations website.

About Helus Pharma

Helus Pharma, the commercial operating name of Cybin Inc. is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

Helus Pharma is working to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s anticipated participation at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit; and plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company’s operations; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three months ended June 30, 2026, and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca/ and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
Matthew.beck@astrpartners.com

Gabriel Fahel
Chief Legal Officer
Helus Pharma
1-866-292-4601
irteam@helus.com – or – media@helus.com

Media Contact:
Victoria Verdeja
RXMD
Public Relations Director
(212) 537-9495
vverdeja@rxmedyn.com